Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jpedsurg.2024.162132 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Getting the Most Out of Your Genome-Wide Association Study Using Polygenic Risk Scores.
J Clin Microbiol
July 2023
Department of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Determining the risk of a phenotypic outcome is a complex balance of variants "for" or "against" the phenotype, which in the context of human genetic diseases have been summarized using polygenic risk scores. In a previously published article (K. T.
View Article and Find Full Text PDFInsights from prospective multi-omic profiling of lymphocytes in resected lung cancer.
Ann Oncol
January 2022
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA; Weill Cornell Medical College, New York, USA; Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, USA.
Antidrug Antibodies and Drug Development: Challenges in the Immunotherapy Era.
Clin Cancer Res
May 2021
Early Phase Clinical Trials Unit START-Madrid-FJD, Fundación Jiménez Diaz University Hospital, Madrid, Spain.
Novel antibody formats such as bispecifics have increased risk of immunogenicity, impacting safety and efficacy. LY3415244, a novel T-cell immunoglobulin and mucin-domain-containing molecule-3 (TIM3)-PDL1 (programmed death (ligand) 1) bispecific caused neutralizing antibody-drug antibodies (ADA) in 12 of 12 patients and required study termination. Novel approaches are needed to ameliorate and manage this undesirable effect of therapeutic antibodies.
View Article and Find Full Text PDFPurpose: Investigate the safety and efficacy of LY3415244, a TIM-3/PD-L1 bispecific antibody that blocks TIM-3 and PD-L1 in patients with advanced solid tumors.
Patients And Methods: A phase I, multicenter, open-label study was conducted in patients with advanced solid tumors. Patients were dosed every 2 weeks intravenously with flat doses of LY3415244 escalating from 3 to 70 mg.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!